Donation

Understanding the VRd Regimen for Newly Diagnosed Myeloma

Understanding the VRd Regimen for Newly Diagnosed Myeloma discusses a highly effective “triplet” (three-drug) therapy that has proven to be both highly effective and well tolerated. The VRd regimen combines three classes of drugs, with each drug attacking myeloma in a different way while enhancing the activity of the others. The combination of Velcade® (bortezomib) with Revlimid® (lenalidomide) and dexamethasone is currently considered the standard of care for patients with newly diagnosed myeloma.

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.